Prof. Dr. med. Arndt Hartmann



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance () Branz A, Matek C, Lange F, Bahlinger V, Klümper N, Hölzel M, Strissel P, et al. Journal article Assessment of a fully-automated diagnostic AI software in prostate MRI: Clinical evaluation and histopathological correlation () Bayerl N, Adams LC, Cavallaro AJ, Bäuerle T, Schlicht M, Wullich B, Hartmann A, et al. Journal article PD-L1-Expression in in primary and recurrent vulvar squamous cell cancer (2025) Stübs F, Knöll A, Hartmann A, Leikauf LS, Matek C, John N, Häberle L, et al. Journal article Neues aus der Uropathologie (2025) Hartmann A Journal article Machine Learning Accurately Predicts Muscle Invasion of Bladder Cancer Based on Three miRNAs (2025) Eckhart L, Rau S, Eckstein M, Stahl PR, Ayoubian H, Heinzelbecker J, Zohari F, et al. Journal article Style-Extracting Diffusion Models for Semi-supervised Histopathology Segmentation (2025) Öttl M, Wilm F, Steenpaß J, Qiu J, Rübner M, Hartmann A, Beckmann M, et al. Conference contribution, Original article Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas. (2025) Stögbauer F, Wirth M, Lauterbach M, Wollenberg B, Schmidl B, Hoch CC, Ourailidis I, et al. Journal article Undifferenzierte und dedifferenzierte Nierenzellkarzinome: Morphomolekulare Aspekte und Differenzialdiagnose im Hinblick auf neuere Entwicklungen (2025) Agaimy A, Hartmann A Journal article Comprehensive genomic characterization of early-stage bladder cancer (2025) Prip F, Lamy P, Lindskrog SV, Strandgaard T, Nordentoft I, Birkenkamp-Demtröder K, Birkbak NJ, et al. Journal article Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers. (2025) Häberle L, Erber R, Gaß P, Hein A, Niklos M, Volz B, Hack C, et al. Journal article